Treatments

*June 2024* This is an excellent presentation at ASCO 2024 by Dr. Jordi Remon Masip on treatment at time of resistance to EGFR TKIs. Those of you wanting to know what the latest is in options after progression on Tagrisso should look at the slide deck of his presentation here.

*June 2024* Purpose Leptomeningeal metastases (LMs) exhibit a high incidence in patients with epidermal growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC) post-treatment with first- or second-generation EGFR tyrosine kinase inhibitors (TKIs). This investigation evaluates the efficacy, safety, and pharmacokinetics of 80 mg once daily osimertinib in patients with…

*June 2024* Keypoints:  A randomized comparative effectiveness trial confirmed that early palliative care delivered through video is just as effective as in-person visits on maintaining quality of life in patients with advanced lung cancer. At 24 weeks, quality of life as assessed by the Functional Assessment of Cancer Therapy-Lung (FACT-L)…

*May 2024* Key Takeaways: In the CHRYSALIS-2 study, amivantamab plus lazertinib demonstrated significant antitumor activity, including a 51% objective response rate and durable responses, in patients with atypical EGFR-mutated advanced NSCLC, regardless of prior treatment with afatinib. In the CHRYSALIS-2 study's Cohort C, evaluating amivantamab (ami) plus lazertinib (laz) in atypical…

*May 2024* Key takeaway: Amivantamab  combined with lazertinib significantly improved PFSl compared to osimertinib  in treatment-naïve patients with EGFR-mutant advanced non-small cell lung cancer, including those with high-risk features, establishing it as a promising new standard of care. Amivantamab (ami), an EGFR-MET bispecific antibody with immune cell-directing activity, combined with lazertinib…

*May 2024* Key Points: In patients with refractory EGFR-mutated advanced non–small cell lung cancer (NSCLC), subcutaneous amivantamab plus lazertinib was noninferior to intravenous (IV) amivantamab, as assessed by pharmacokinetics and objective response rate (ORR). Administration time was reduced from 2 to 5 hours with IV amivantamab to less than 5 minutes…

*May 2024* As targeted therapy gets more precise, the treatment paradigms shift, particularly for patients with non–small cell lung cancer (NSCLC). This patient population has seen substantial changes in standard of care as more nuance is added to the understanding of how resistance and mutations within the tumor are targeted.…

*June 2024* In this START HERE lung cancer webinar, Dr. Christina Baik, Associate Professor of Medicine at the University of Washington and Fred Hutchinson Cancer Center, provides valuable insights into priorities for newly diagnosed patients. Dr. Baik also discusses essential tools for managing disease progression and recurrence. Watch the program…

*April 2024* The addition of the selective MET TKI savolitinib (Orpathys) to osimertinib (Tagrisso) demonstrated consistent safety and higher clinical activity vs savolitinib plus placebo in patients with EGFR-mutated, MET-amplified advanced non–small cell lung cancer (NSCLC) whose disease had previously progressed on osimertinib, according to findings from a proteogenomic analysis presented at…